Medpace Holdings, Inc.
MEDP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.34 | -1.58 | -76.35 | 1.02 |
| FCF Yield | 1.76% | 1.54% | 1.25% | 1.78% |
| EV / EBITDA | 98.65 | 79.58 | 74.25 | 73.28 |
| Quality | ||||
| ROIC | 22.33% | 24.34% | 14.20% | 11.00% |
| Gross Margin | 29.84% | 29.84% | 31.93% | 33.23% |
| Cash Conversion Ratio | 2.22 | 1.65 | 1.10 | 1.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.80% | 10.09% | 11.32% | 13.04% |
| Free Cash Flow Growth | 84.19% | 22.94% | -36.71% | 32.11% |
| Safety | ||||
| Net Debt / EBITDA | -0.94 | 0.88 | -2.61 | -4.09 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 45.72 | 47.18 | 33.54 | 41.55 |